leadf
logo-loader
viewANGLE PLC

ANGLE hails results from landmark ovarian cancer study which underlines potential of its liquid biopsy

Its Parsortix system was able to detect cancer in 95% of the cases, achieving a lower false positive rate than existing method of detection

ANGLE hails results from landmark ovarian cancer study which underlines potential of its liquid biop
The technology could ultimately help dictate treatment options, streamlining the process

AIM-listed med-tech firm ANGLE plc (LON:AGL,OTCQX:ANPCY) said its ground-breaking liquid biopsy outperformed the current tests used to tell whether a pelvic mass is malignant or benign.

Its Parsortix system was able to detect cancer in 95% of the cases, achieving a lower false positive rate than existing method of detection.

WATCH: ANGLE boss delighted by study results

READ: Our Big Picture overview of the company

ANGLE’s technology was used in harness with a specially-developed algorithm using certain patient data.

Results came from a study of 400 people at two centres – Vienna and New York State.

ANGLE believes the Parsortix blood test has the potential to aid the diagnosis of ovarian cancer before a biopsy or surgery is performed.

Diagnosis before biopsy

Why does this matter? Well, it will allow those with disease to be referred directly to gynaecologic oncology surgeons.

At the same time, it should ensure patients with benign tumours are be cared for in their communities. 

This streamlined strategy has the potential to cut costs and accelerate treatment.

ANGLE’s founder and chief executive said of the latest results: “This success enables ANGLE to move forward into the validation phase for the use of Parsortix in its first clinical application. 

“We believe ANGLE is building momentum towards securing a leading and well differentiated commercial position in the emerging multi-billion dollar liquid biopsy market."

---adds CEO interview---

 

Quick facts: ANGLE PLC

Price: 48.5 GBX

AIM:AGL
Market: AIM
Market Cap: £83.81 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Angle’s Newland reflects on excellent year as cancer patient trials advance

Angle Plc (LON:AGL, OTCMKTS:ANPCY) is poised to revolutionise cancer treatment with its Parsortix system, here we catch up with chief executive Andrew Newland. As Newland explains Parsortix can capture cancer cells from blood, which is very significant for the emerging field of...

on 07/28/2016

2 min read